Trade Report: The Johnson & Johnson (JNJ) gets Hold status at Vetr Inc.

The Johnson & Johnson (JNJ) gets Hold status at Vetr Inc.

Johnson & Johnson (NYSE:JNJ) was downgraded by equities researchers at Vetr from a “buy” rating to a “hold” rating in a research note issued on Monday. They presently have a $117.54 target price on the stock. Vetr‘s price objective points to a potential upside of 2.99% from the company’s previous close.

A number of other brokerages also recently weighed in on JNJ. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Monday, July 11th. Deutsche Bank AG reaffirmed a “buy” rating and issued a $142.00 target price on shares of Johnson & Johnson in a report on Friday, August 19th. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 target price on the stock in a report on Friday, August 5th. Leerink Swann reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Sunday, September 11th. Finally, Argus reaffirmed a “buy” rating and issued a $145.00 target price on shares of Johnson & Johnson in a report on Friday, October 21st. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $120.79.

Johnson & Johnson (NYSE:JNJ) traded up 0.94% during trading on Monday, reaching $114.13. The company’s stock had a trading volume of 3,433,340 shares. The company’s 50 day moving average price is $116.14 and its 200-day moving average price is $118.35. Johnson & Johnson has a 1-year low of $94.28 and a 1-year high of $126.07. The stock has a market cap of $310.49 billion, a P/E ratio of 20.03 and a beta of 0.75.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 18th. The company reported $1.68 EPS for the quarter, topping the Zacks’ consensus estimate of $1.66 by $0.02. Johnson & Johnson had a return on equity of 25.30% and a net margin of 22.03%. The firm had revenue of $17.80 billion for the quarter, compared to analyst estimates of $17.71 billion. During the same quarter last year, the company earned $1.49 EPS. The company’s revenue was up 4.2% on a year-over-year basis. Equities analysts forecast that Johnson & Johnson will post $6.72 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be paid a dividend of $0.80 per share. The ex-dividend date is Friday, November 18th. This represents a $3.20 dividend on an annualized basis and a yield of 2.80%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.29. Johnson & Johnson’s payout ratio is 56.64%.

In related news, Director Charles Prince purchased 875 shares of the business’s stock in a transaction on Friday, October 21st. The stock was acquired at an average price of $114.11 per share, for a total transaction of $99,846.25. Following the purchase, the director now owns 26,520 shares of the company’s stock, valued at $3,026,197.20. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.11% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Johnson & Johnson by 2.2% in the second quarter. Vanguard Group Inc. now owns 184,512,652 shares of the company’s stock worth $22,381,384,000 after buying an additional 3,924,090 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in Johnson & Johnson by 1.3% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 74,800,935 shares of the company’s stock worth $8,836,234,000 after buying an additional 924,692 shares during the period. BlackRock Fund Advisors increased its position in Johnson & Johnson by 3.0% in the third quarter. BlackRock Fund Advisors now owns 43,337,560 shares of the company’s stock worth $5,119,466,000 after buying an additional 1,248,515 shares during the period. Massachusetts Financial Services Co. MA increased its position in Johnson & Johnson by 1.0% in the second quarter. Massachusetts Financial Services Co. MA now owns 28,267,979 shares of the company’s stock worth $3,428,905,000 after buying an additional 283,866 shares during the period. Finally, BlackRock Group LTD increased its position in Johnson & Johnson by 1.2% in the second quarter. BlackRock Group LTD now owns 25,315,774 shares of the company’s stock worth $3,070,804,000 after buying an additional 289,995 shares during the period. Institutional investors and hedge funds own 65.19% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Related posts

Leave a Comment